Thr210
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.6.0.1
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Thr210  -  PLK1 (mouse)

Site Information
YEGERKKtLCGtPNY   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 448139

In vivo Characterization
Methods used to characterize site in vivo:
immunoassay ( 1 ) , immunoprecipitation ( 4 ) , mass spectrometry ( 2 , 6 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 ) , mutation of modification site ( 4 ) , phospho-antibody ( 1 , 4 , 5 ) , western blotting ( 4 , 5 )
Relevant cell line - cell type - tissue:
'brain, embryonic' ( 8 ) , BaF3 ('B lymphocyte, precursor') [JAK3 (human), transfection] ( 2 ) , brain ( 6 ) , embryo ( 6 ) , HeLa (cervical) ( 4 , 10 ) , HeLa_NOC (cervical) ( 10 ) , liver ( 6 ) , MEF (fibroblast) ( 4 ) , MEF (fibroblast) [TSC2 (mouse), homozygous knockout] ( 9 ) , oocyte ( 1 ) , spleen ( 12 , 15 ) , testis ( 11 , 14 ) , thymus ( 13 )

Upstream Regulation
Regulatory protein:
SHP-2 (human) ( 4 )
Putative in vivo kinases:
AurA (mouse) ( 1 )
Treatments:
BI_4834 ( 10 ) , hesperadin ( 10 ) , MG132 ( 10 ) , nocodazole ( 10 )

Downstream Regulation
Effects of modification on PLK1:
enzymatic activity, induced ( 1 , 4 ) , intracellular localization ( 5 )
Effects of modification on biological processes:
cell cycle regulation ( 1 , 4 )

References 

1

Blengini CS, et al. (2021) Aurora kinase A is essential for meiosis in mouse oocytes. PLoS Genet 17, e1009327
33901174   Curated Info

2

Degryse S, et al. (2017) Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia. Leukemia
28852199   Curated Info

3

Sacco F, et al. (2016) Glucose-regulated and drug-perturbed phosphoproteome reveals molecular mechanisms controlling insulin secretion. Nat Commun 7, 13250
27841257   Curated Info

4

Liu X, et al. (2016) Gain-of-function mutations of Ptpn11 (Shp2) cause aberrant mitosis and increase susceptibility to DNA damage-induced malignancies. Proc Natl Acad Sci U S A 113, 984-9
26755576   Curated Info

5

Solc P, et al. (2015) Multiple Requirements of PLK1 during Mouse Oocyte Maturation. PLoS One 10, e0116783
25658810   Curated Info

6

Stokes MP, et al. (2012) PTMScan Direct: Identification and Quantification of Peptides from Critical Signaling Proteins by Immunoaffinity Enrichment Coupled with LC-MS/MS. Mol Cell Proteomics 11, 187-201
22322096   Curated Info

7

Mielgo A, et al. (2011) A MEK-independent role for CRAF in mitosis and tumor progression. Nat Med 17, 1641-5
22081024   Curated Info

8

Guo A (2011) CST Curation Set: 12476; Year: 2011; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

9

Yu Y, et al. (2011) Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling. Science 332, 1322-6
21659605   Curated Info

10

Hegemann B, et al. (2011) Systematic phosphorylation analysis of human mitotic protein complexes. Sci Signal 4, rs12
22067460   Curated Info

11

Guo A (2009) CST Curation Set: 8168; Year: 2009; Biosample/Treatment: tissue, testis/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y/M)Xp[ST](L/I/M)
Curated Info

12

Guo A (2009) CST Curation Set: 8166; Year: 2009; Biosample/Treatment: tissue, spleen/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y/M)Xp[ST](L/I/M)
Curated Info

13

Guo A (2009) CST Curation Set: 8170; Year: 2009; Biosample/Treatment: tissue, thymus/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y/M)Xp[ST](L/I/M)
Curated Info

14

Guo A (2009) CST Curation Set: 8167; Year: 2009; Biosample/Treatment: tissue, testis/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y/M)Xp[ST](L/I/M)
Curated Info

15

Guo A (2009) CST Curation Set: 8165; Year: 2009; Biosample/Treatment: tissue, spleen/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y/M)Xp[ST](L/I/M)
Curated Info